206 related articles for article (PubMed ID: 21447864)
1. The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women.
Zhang J; Chung E; Yones C; Persson A; Mahnke L; Eley T; Xu X; Bertz R
Antivir Ther; 2011; 16(2):157-64. PubMed ID: 21447864
[TBL] [Abstract][Full Text] [Related]
2. The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women.
Sevinsky H; Eley T; Persson A; Garner D; Yones C; Nettles R; Krantz K; Bertz R; Zhang J
Antivir Ther; 2011; 16(2):149-56. PubMed ID: 21447863
[TBL] [Abstract][Full Text] [Related]
3. Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO.
Poindexter AN; Burkman R; Fisher AC; LaGuardia KD
Int J Fertil Womens Med; 2003; 48(4):163-72. PubMed ID: 13677549
[TBL] [Abstract][Full Text] [Related]
4. Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol.
Song IH; Borland J; Chen S; Wajima T; Peppercorn AF; Piscitelli SC
Ann Pharmacother; 2015 Jul; 49(7):784-9. PubMed ID: 25862012
[TBL] [Abstract][Full Text] [Related]
5. Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate.
Bifano M; Sevinsky H; Hwang C; Kandoussi H; Jiang H; Grasela D; Bertz R
Antivir Ther; 2014; 19(5):511-9. PubMed ID: 24343001
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety and cycle control of five oral contraceptive regimens containing norgestimate and ethinyl estradiol.
LaGuardia KD; Shangold G; Fisher A; Friedman A; Kafrissen M
Contraception; 2003 Jun; 67(6):431-7. PubMed ID: 12814811
[TBL] [Abstract][Full Text] [Related]
7. Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women.
Kasserra C; Li J; March B; O'Mara E
Clin Ther; 2011 Oct; 33(10):1503-14. PubMed ID: 22015327
[TBL] [Abstract][Full Text] [Related]
8. Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.
Schwartz JI; Liu F; Wang YH; Pramanik B; Johnson-Levonas AO; Gutierrez MJ; Lai E; Wagner JA
Am J Ther; 2009; 16(6):487-95. PubMed ID: 19940609
[TBL] [Abstract][Full Text] [Related]
9. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.
Burger DM; Agarwala S; Child M; Been-Tiktak A; Wang Y; Bertz R
Antimicrob Agents Chemother; 2006 Oct; 50(10):3336-42. PubMed ID: 17005814
[TBL] [Abstract][Full Text] [Related]
10. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.
Pham PA; Flexner C; Parsons T; Vasist L; Fuchs E; Carson K; Agarwala S; Barditch-Crovo P
J Acquir Immune Defic Syndr; 2007 Jun; 45(2):201-5. PubMed ID: 17414932
[TBL] [Abstract][Full Text] [Related]
11. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.
Conradie F; Zorrilla C; Josipovic D; Botes M; Osiyemi O; Vandeloise E; Eley T; Child M; Bertz R; Hu W; Wirtz V; McGrath D
HIV Med; 2011 Oct; 12(9):570-9. PubMed ID: 21569187
[TBL] [Abstract][Full Text] [Related]
12. Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen(®), a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women.
Upreti VV; Hsiang CB; Li L; Xu X; LaCreta FP; Boulton DW
Diabetes Obes Metab; 2012 Dec; 14(12):1155-7. PubMed ID: 22776778
[TBL] [Abstract][Full Text] [Related]
13. Influence of alitretinoin on the pharmacokinetics of the oral contraceptive ethinyl estradiol/norgestimate.
Schmitt-Hoffmann AH; Roos B; Sauer J; Schleimer M; Schoetzau A; Leese PT; Weidekamm E; Maares J
Clin Exp Dermatol; 2011 Apr; 36 Suppl 2():4-11. PubMed ID: 21443598
[TBL] [Abstract][Full Text] [Related]
14. Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir.
Gutierrez-Valencia A; Ruiz-Valderas R; Torres-Cornejo A; Viciana P; Espinosa N; Castillo-Ferrando JR; Lopez-Cortes LF
Clin Infect Dis; 2014 Jan; 58(2):268-73. PubMed ID: 24145880
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.
Hulskotte EG; Feng HP; Xuan F; van Zutven MG; Treitel MA; Hughes EA; O'Mara E; Youngberg SP; Wagner JA; Butterton JR
Clin Infect Dis; 2013 Mar; 56(5):718-26. PubMed ID: 23155151
[TBL] [Abstract][Full Text] [Related]
16. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females.
Trapnell CB; Connolly M; Pentikis H; Forbes WP; Bettenhausen DK
Ann Pharmacother; 2007 Feb; 41(2):222-8. PubMed ID: 17284510
[TBL] [Abstract][Full Text] [Related]
17. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives.
Kearney BP; Mathias A
Pharmacotherapy; 2009 Aug; 29(8):924-9. PubMed ID: 19637945
[TBL] [Abstract][Full Text] [Related]
18. Effects of rimegepant 75 mg daily on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female participants.
Bhardwaj R; Stringfellow JC; Morris B; Croop RS; Bertz RJ
Headache; 2023 May; 63(5):652-662. PubMed ID: 37140071
[TBL] [Abstract][Full Text] [Related]
19. Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects.
German P; Moorehead L; Pang P; Vimal M; Mathias A
J Clin Pharmacol; 2014 Nov; 54(11):1290-8. PubMed ID: 24925712
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies.
Schipani A; Dickinson L; Boffito M; Austin R; Owen A; Back D; Khoo S; Davies G
J Acquir Immune Defic Syndr; 2013 Jan; 62(1):60-6. PubMed ID: 23011396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
